Boothbay Fund Management’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-20,150
| Closed | -$2.15M | – | 2405 |
|
|
2025
Q3 | $2.15M | Sell |
20,150
-462,759
| -96% | -$48.3M | 0.03% | 551 |
|
|
2025
Q2 | $45.7M | Buy |
482,909
+8,980
| +2% | +$665K | 0.89% | 11 |
|
|
2025
Q1 | $30.1M | Buy |
473,929
+41,759
| +10% | +$2.5M | 0.79% | 11 |
|
|
2024
Q4 | $20.1M | Buy |
432,170
+23,100
| +6% | +$867K | 0.5% | 26 |
|
|
2024
Q3 | $11.8M | Sell |
409,070
-446,328
| -52% | -$11M | 0.27% | 66 |
|
|
2024
Q2 | $12.4M | Buy |
855,398
+216,280
| +34% | +$3.16M | 0.29% | 51 |
|
|
2024
Q1 | $10.3M | Buy |
639,118
+571,194
| +841% | +$9.88M | 0.2% | 74 |
|
|
2023
Q4 | $1.35M | Buy |
67,924
+11,726
| +21% | +$173K | 0.03% | 629 |
|
|
2023
Q3 | $916K | Buy |
56,198
+4,914
| +10% | +$94.6K | 0.02% | 807 |
|
|
2023
Q2 | $1.08M | Buy |
51,284
+17,323
| +51% | +$369K | 0.02% | 793 |
|
|
2023
Q1 | $682K | Sell |
33,961
-3,928
| -10% | -$84.8K | 0.01% | 1152 |
|
|
2022
Q4 | $990K | Sell |
37,889
-8,910
| -19% | -$119K | 0.02% | 902 |
|
|
2022
Q3 | $478K | Buy |
46,799
+8,519
| +22% | +$71.8K | 0.01% | 1266 |
|
|
2022
Q2 | $160K | Buy |
+38,280
| New | +$164K | ﹤0.01% | 1846 |
|
Other funds holding VRNA
Boothbay Fund Management's VRNA Position: Q4 2025 in Review
Boothbay Fund Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 20,150 shares — an estimated $2.15M sold.
Boothbay Fund Management first reported a position in VRNA in Q2 2022 and held it in 14 quarters. The position peaked at $45.7M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Boothbay Fund Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Boothbay Fund Management sold 20,150 Verona Pharma shares in Q4 2025, an estimated $2.15M.
- Boothbay Fund Management first reported a position in Verona Pharma in Q2 2022 and held it in 14 quarters.
- Boothbay Fund Management's Verona Pharma position peaked at $45.7M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.